An interesting clinical observation with ABT-199 was that favorable response was mainly limited to patients carrying t(11;14) translocation, which only represents ~15% of all MM patients suggesting that myeloma cells in these patients rely predominantly, if not exclusively on Bcl-2 [19]. Here, BCL2 is linked to plasma cell myeloma.